Trials / Completed
CompletedNCT00802542
In-practice Evaluation of Atacand 16mg Antihypertensive Effect
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses
Conditions
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-12-05
- Last updated
- 2010-12-03
Locations
4 sites across 1 country: Latvia
Source: ClinicalTrials.gov record NCT00802542. Inclusion in this directory is not an endorsement.